Soligenix Stock Nearly Doubles Before the Bell as Ebola Vaccine Hopes Put Tiny Biotech Back in Play
Soligenix Inc. shares jumped 94.6% to $1.00 in pre-market trading after linking its ThermoVax technology to the Bundibugyo Ebola outbreak in Congo and Uganda. The WHO declared the outbreak a Public Health Emergency of International Concern, with 105 confirmed cases and 10 deaths in DRC, and seven cases in Uganda. No FDA-approved vaccine exists for Bundibugyo virus. Soligenix has no product orders or revenue.